Sentence examples for viable therapeutics from inspiring English sources

The intragenic heterogeneity encountered in many dominant disease-causing genes represents a significant challenge with respect to development of economically viable therapeutics.

This review focuses on the state of the art of RAS inhibition, the approaches taken to achieve this goal, and the challenges of translating these discoveries into viable therapeutics.

A design scheme is also proposed on the way in which the engineering of advanced delivery systems should be practiced towards their transformation from laboratory inventions to clinically viable therapeutics.

Additional studies are clearly needed before tocilizumab or other IL-6 antagonists can be considered viable therapeutics in human SLE.

The research mentioned thus far implicates DNA methylation in the fibrotic response and alludes to the potential use of DNMT inhibitors as viable therapeutics.

Colloidal carriers have the potential to enable clinical use of a number of therapeutics, such as siRNA and peptides, which if administered in their naked form can degrade before demonstrating a viable therapeutic effect.

Given the spectrum of RAS-activating mutations, it is clear that targeting this pathway may be a viable therapeutic option for patients with recurrent or advanced stage mucinous ovarian carcinoma, however caution should be exercised in selecting one or more personalized therapeutics given the frequency of non-redundant RAS-activating alterations.

Although miRNAs are emerging as viable cancer therapeutics, their efficacy remains largely dependent on the development of effective delivery strategies.

Furthermore, miRNAs are frequently deregulated in human diseases, indicating that they could serve as viable targets for therapeutics.

Promising advances have been made through the use of modified oligonucleotides and novel biodelivery methods, and the field is expected to progress rapidly in its movement towards viable miRNA-based therapeutics.

An expanding inventory of genetic gain- or loss-of-function studies of specific miRNAs together with recent data from pharmacological modulation of individual miRNAs or miRNA families in animal disease models implies that miRNAs are viable targets for therapeutics (van Rooij, 2012; van Rooij & Olson, 2012; Stenvang et al, 2012; Thorsen et al, 2012).